Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension

References

• Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253:643–52
   PubMed Web of Science ®Google Scholar
• Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension 2004;43:525–30
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116: 4–15
   Google Scholar
• Ofman JJ, MacLean CH, Straus WL, Morton SC, et al. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804–12
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G, Tugwell P, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002:CD002296
   Google Scholar
• Ofman JJ, Maclean CH, Straus WL, Morton SC, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003;49:508–18
   PubMed Web of Science ®Google Scholar
• Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490–6
   PubMed Web of Science ®Google Scholar
• Matchaba P, Gitton X, Krammer G, Ehrsam E, et al. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or = 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther 2005;27:1196–214
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644–65
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, Halls H, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302–8
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006;296: 1619–32
   Google Scholar
• Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477–84
   PubMed Web of Science ®Google Scholar
• Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289–300
   Google Scholar
• Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619
   Google Scholar
• Garner SE, Fidan DD, Frankish R, Maxwell L. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005:CD005115
   Google Scholar
• Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 2004: CD000189
   Google Scholar
• Aisen PS, Schafer KA, Grundman M, Pfeiffer E, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819–26
   PubMed Web of Science ®Google Scholar
• Bhagat K. Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. East Afr Med J 2001;78:507–9
   PubMedGoogle Scholar
• Collantes E, Curtis SP, Lee KW, Casas N, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002;3:10
   PubMedGoogle Scholar
• Ebel DL, Rhymer AR, Stahl E, Tipping R. Effect of Clinoril (sulindac, MSD), piroxicam and placebo on the hypotensive effect of propranolol in patients with mild to moderate essential hyper tension. Scand J Rheumatol Suppl 1986;62:41–9
   PubMedGoogle Scholar
• Emery P, Zeidler H, Kvien TK, Guslandi M, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106–11
   PubMed Web of Science ®Google Scholar
• Gertz BJ, Krupa D, Bolognese JA, Sperling RS, et al. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin 2002;18:82–91
   PubMed Web of Science ®Google Scholar
• Geusens P, Alten R, Rovensky J, Sloan VS, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract 2004;58:1033–41
   PubMed Web of Science ®Google Scholar
• Goldberg MA. A multicenter study of the safety and efficacy of naproxen: analysis of blood pressure. Semin Arthritis Rheum 1988;17:23–8
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Everitt DE, Monane M, Glynn RJ, et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996;51:M74–9
   PubMed Web of Science ®Google Scholar
• Harvey PJ, Wing LM, Beilby J, Ramsay A, et al. Effect of indo-methacin on blood pressure control during treatment with nitrendipine. Blood Press 1995;4:307–12
   PubMedGoogle Scholar
• Hawkey CJ, Laine L, Simon T, Quan H, et al. Incidence of gastro duodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003;52:820–6
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, et al. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc 2004;52: 666–74
   Google Scholar
• Klassen D, Goodfriend TL, Schuna AA, Young DY, et al. Assess ment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. J Clin Pharmacol 1993;33:971–8
   PubMed Web of Science ®Google Scholar
• Klassen DK, Jane LH, Young DY, Peterson CA. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens 1995;8:146–53
   PubMed Web of Science ®Google Scholar
• Koopmans PP, Thien T, Gribnau FW. The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. Eur J Clin Pharmacol 1987;31:553–7
   Google Scholar
• Koopmans PP, Thien T, Gribnau FW. Influence of nonsteroidal anti-inflammatory drugs on diuretic treatment of mild to moderate essential hypertension. Br Med J (Clin Res Ed) 1984;289:1492–4
   Google Scholar
• Koopmans PP, Thien T, Thomas CM, Van den Berg RJ, et al. The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986;21:417–23
   Google Scholar
• Lisse JR, Perlman M, Johansson G, Shoemaker JR, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003;139:539–46
   PubMed Web of Science ®Google Scholar
• Lohmander LS, McKeith D, Svensson O, Malmenas M, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005;64:449–56
   PubMed Web of Science ®Google Scholar
• Lucker PW, Pawlowski C, Friedrich I, Faiella F, et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 1994;14:29–38
   PubMedGoogle Scholar
• Matsumoto AK, Melian A, Mandel DR, McIlwain HH, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623–30
   PubMed Web of Science ®Google Scholar
• Murray MD, Lazaridis EN, Brizendine E, Haag K, et al. The effect of nonsteroidal antiinflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Am J Med Sci 1997;314:80–8
   PubMed Web of Science ®Google Scholar
• Oparil S, Horton R, Wilkins LH, Irvin J, et al. Antihypertensive effect of enalapril in essential hypertension: role of prostacyclin. Am J Med Sci 1987;294:395–402
   PubMed Web of Science ®Google Scholar
• Palmer R, Weiss R, Zusman RM, Haig A, et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003;16:135–9
   PubMed Web of Science ®Google Scholar
• Puddey IB, Beilin LJ, Vandongen R, Banks R, et al. Differential effects of sulindac and indomethacin on blood pressure in treated essential hypertensive subjects. Clin Sci (Lond) 1985;69:327–36
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Vandormael K, Malice MP, Kalyani RN, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72:50–61
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Gitton X, Jayawardene S, Sloan VS. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose–response studies. Curr Med Res Opin 2005;21:151–61
   PubMed Web of Science ®Google Scholar
• Smith MD, Kupa A, Weatherall M, Henstridge JD, et al. The effect of tiaprofenic acid on blood pressure control in treated hypertensive patients. Curr Med Res Opin 1985;9:388–93
   PubMed Web of Science ®Google Scholar
• Thakur V, Cook ME, Wallin JD. Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. Am J Hypertens 1999;12:925–8
   Google Scholar
• Truitt KE, Sperling RS, Ettinger WH, Jr, Greenwald M, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 2001;13:112–21
   PubMedGoogle Scholar
• White WB, Faich G, Whelton A, Maurath C, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425–30
   PubMed Web of Science ®Google Scholar
• Wong DG, Spence JD, Lamki L, Freeman D, et al. Effect of nonsteroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986;1:997–1001
   PubMed Web of Science ®Google Scholar
• Sowers JR, White WB, Pitt B, Whelton A, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161–8
   PubMed Web of Science ®Google Scholar
• Izhar M, Alausa T, Folker A, Hung E, et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004;43:573–7
   PubMed Web of Science ®Google Scholar
• Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitatitive synthesis in medicine. In Monographs in Epidemiology and Biostatistics, Vol 24. New York: Oxford University Press, 1994
   Google Scholar